Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc

心肌细胞旁分泌血管生成功能的调节

基本信息

  • 批准号:
    7992888
  • 负责人:
  • 金额:
    $ 39.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-07-01 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Emerging observations indicate that the processes of cardiomyocyte growth and cardiac angiogenesis must remain balanced throughout life and suggest that excess cardiac hypertrophy and/or insufficient cardiac angiogenesis in response to stress leads to impaired cardiac function, cardiomyopathy, and heart failure. An imbalance between cardiac growth and cardiac angiogenesis may play an essential role in the development and progression of multiple forms of human heart failure. Intriguingly, several recent studies indicate that the cardiomyocyte itself functions in a paracrine fashion to regulate blood vessel growth in the heart in response to stress. However, the molecular regulation of this paracrine function of cardiomyocytes (the angiogenic potential of cardiomyocytes) is not well understood. Our central hypothesis is that under conditions of stress that lead to cardiac hypertrophy, platelet derived growth factor receptor beta (PDGFR-) is an upstream regulator of the angiogenic potential of cardiomyocytes. In support of this hypothesis, we have shown that cardiomyocyte specific Pdgfrb knockout mice exposed to pressure overload stress develop cardiac dysfunction, ventricular dilatation and heart failure, associated with defective coronary microvascular function. These findings demonstrate that PDGFR- signaling is an essential and heretofore unappreciated mediator of the cardiac stress response. To further understand the role of PDGFR- signaling as a regulator of the angiogenic potential of cardiomyocytes, we will determine if cardiomyocyte PDGFR- signaling regulates coronary angiogenesis in response to pathologic stressors that lead to cardiac hypertrophy using a Pdgfrb knockout model and also via administration of anti-cancer agents whose targets include PDGFR- (Aim One). We will further determine if cardiomyocyte PDFGR- signaling is required to promote coronary angiogenesis which accompanies physiologic cardiac growth observed in early postnatal life or in adult life in response to exercise training using a Pdgfrb knockout model (Aim Two). Finally, we will determine the mechanism(s) by which PDGFR- signaling regulates the angiogenic potential of cardiomyocytes using an in vitro model of cultured cardiomyocytes in which PDGFR- is deleted. Confirmation of our overall hypothesis through the experiments proposed in this application would suggest that PDGFR- in the heart may be a novel area of concern in evaluating and treating selected forms of human heart failure, and in addition, may inform strategies to prevent and/or treat cardiotoxicity in cancer patients treated with agents that target PDGFR signaling. PUBLIC HEALTH RELEVANCE: Studies proposed in this application will seek to understand the role of platelet derived growth factor beta (PDGFR-), a protein expressed on the cell surface of a number of cell types including heart muscle cells, in the regulation of blood vessel growth in the heart during heart muscle growth which occurs as a result of a variety of stressors, some of which are directly linked to the development of heart failure. Insights gained from this study may be used to develop novel therapeutic strategies for the treatment of human heart failure due to multiple etiologies, and may also be useful to help develop strategies to prevent clinical cardiac toxicity due to anti-cancer agents that target PDGFR signaling.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WADIH ARAP其他文献

WADIH ARAP的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WADIH ARAP', 18)}}的其他基金

Designing a transcriptome-based, targeted theranostic platform for prostate cancer
设计基于转录组的前列腺癌靶向治疗平台
  • 批准号:
    10553662
  • 财政年份:
    2020
  • 资助金额:
    $ 39.5万
  • 项目类别:
Designing a transcriptome-based, targeted theranostic platform for prostate cancer
设计基于转录组的前列腺癌靶向治疗平台
  • 批准号:
    10335200
  • 财政年份:
    2020
  • 资助金额:
    $ 39.5万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    9982236
  • 财政年份:
    2018
  • 资助金额:
    $ 39.5万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    10202502
  • 财政年份:
    2018
  • 资助金额:
    $ 39.5万
  • 项目类别:
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
针对恩杂鲁胺耐药性前列腺癌的靶向纳米药物原型
  • 批准号:
    10464889
  • 财政年份:
    2018
  • 资助金额:
    $ 39.5万
  • 项目类别:
Targeting Lymphatic Vessels for Ligand Directed Imaging
靶向淋巴管进行配体定向成像
  • 批准号:
    9234681
  • 财政年份:
    2016
  • 资助金额:
    $ 39.5万
  • 项目类别:
Targeting Lymphatic Vessels for Ligand Directed Imaging
靶向淋巴管进行配体定向成像
  • 批准号:
    10049234
  • 财政年份:
    2016
  • 资助金额:
    $ 39.5万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8756663
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8669059
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:
Novel Clinical Diagnostic Targets For Detection of Invasive Mold Aspergillosis
检测侵袭性霉菌曲霉病的新临床诊断目标
  • 批准号:
    8077208
  • 财政年份:
    2010
  • 资助金额:
    $ 39.5万
  • 项目类别:

相似国自然基金

基于PXDN-周细胞-血管渗漏轴探讨有氧运动改善肺血管重构机制研究
  • 批准号:
    82370422
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
NEDD4介导IGFBP7泛素化参与有氧运动抑制泛凋亡改善心肌缺血再灌注损伤的机制研究
  • 批准号:
    82302873
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
有氧康复运动抑制心外膜脂肪组织Th17细胞分化改善HFpEF所致心房颤动实验研究
  • 批准号:
    82372581
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
代谢产物丁酸介导的PKM2乳酸化修饰调控小胶质细胞极化参与有氧运动发挥脑梗死后神经保护作用的机制研究
  • 批准号:
    82302861
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
有氧运动依赖ABCG1调节的GSK-3β/Nrf2/ARE抗氧化机制预防化疗药物5氟尿嘧啶诱导的血管内皮损伤机制探索
  • 批准号:
    82360608
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
  • 批准号:
    10734120
  • 财政年份:
    2023
  • 资助金额:
    $ 39.5万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes bycardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8669059
  • 财政年份:
    2013
  • 资助金额:
    $ 39.5万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8271279
  • 财政年份:
    2010
  • 资助金额:
    $ 39.5万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8102060
  • 财政年份:
    2010
  • 资助金额:
    $ 39.5万
  • 项目类别:
Regulation of the paracrine angiogenic function of cardiac myocytes by cardiomyoc
心肌细胞旁分泌血管生成功能的调节
  • 批准号:
    8271279
  • 财政年份:
    2010
  • 资助金额:
    $ 39.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了